XML 66 R54.htm IDEA: XBRL DOCUMENT
v3.22.4

License Agreements - Syros (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2022 shares | Jan. 31, 2018 USD ($) programTarget | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) $ / shares | Dec. 31, 2018 USD ($) $ / shares shares
License agreements |  |  |  |  |  |
Purchase price of common stock |  |  |  |  | $ 150,000 |
Per share price (in dollars per share) | $ / shares |  |  |  |  | $ 41.33 |
Unrealized gain (loss) on long term investments |  |  | $ (87,590) | $ (24,072) | $ 10,426 |
Syros Pharmaceuticals, Inc. |  |  |  |  |  |
License agreements |  |  |  |  |  |
Number of program targets | programTarget |  | 7 |  |  |  |
Fair value of shares on the issuance date |  |  | 300 | 3,100 |  |
Unrealized gain (loss) on long term investments |  |  | $ (2,700) | $ (7,100) | $ 3,700 |
Syros Pharmaceuticals, Inc. | Stock purchase agreement |  |  |  |  |  |
License agreements |  |  |  |  |  |
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares |  |  |  |  |  | 800,000
Purchase price of common stock |  |  |  |  |  | $ 10,000
Per share price (in dollars per share) | $ / shares |  |  |  |  |  | $ 12.61
Syros Pharmaceuticals, Inc. | Amended stock purchase agreement |  |  |  |  |  |
License agreements |  |  |  |  |  |
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares |  |  |  |  |  | 100,000
Purchase price of common stock |  |  |  |  |  | $ 1,400
Per share price (in dollars per share) | $ / shares |  |  |  |  |  | $ 9.55
Syros Pharmaceuticals, Inc. | Maximum |  |  |  |  |  |
License agreements |  |  |  |  |  |
Target selection and option exercise fee payment |  | $ 54,000 |  |  |  |
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum |  |  |  |  |  |
License agreements |  |  |  |  |  |
Additional milestone payments under the license agreement |  | 50,000 |  |  |  |
Syros Pharmaceuticals, Inc. | Commercialization Milestones | Maximum |  |  |  |  |  |
License agreements |  |  |  |  |  |
Additional milestone payments under the license agreement |  | $ 65,000 |  |  |  |
Stock purchase agreement | Syros Pharmaceuticals, Inc. |  |  |  |  |  |
License agreements |  |  |  |  |  |
Conversion ratio | 0.1 |  |  |  |  |
Investment owned (in shares) | shares | 93,753 |  |  |  |  |

X
- Definition Represents the additional milestone payments to be made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the target selection and option exercise fee payments to be made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the number of program targets identified. + References No definition available. + Details
Name: | incy_NumberOfProgramTargets
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the purchase of common stock under Stock Purchase Agreement. + References No definition available. + Details
Name: | incy_PurchaseOfCommonStockUnderStockPurchaseAgreement
Namespace Prefix: | incy_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value of the entity's equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_EquityFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents the aggregate cost of investments accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestmentAggregateCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -URI https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770 + Details
Name: | us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AmendedStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_SyrosPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |